Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Bone · FDA Approved

Vosoritide (Voxzogo)

FDA-approved

Explore lawful clinical options for injury recovery and tissue repairOr: how to ask your own doctor →
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A C-type natriuretic peptide (CNP) analog that acts as an agonist at natriuretic peptide receptor B (NPR-B) on growth plate chondrocytes. Achondroplasia is caused by activating FGFR3 mutations that impair endochondral ossification, and vosoritide acts by antagonizing this FGFR3 signaling to promote bone growth (PMID 40821249).

It is described as the first targeted therapy approved for achondroplasia (PMID 40821249).

02 · Research summary & key findings

FDA-approved in 2021 (Voxzogo) for children with achondroplasia whose growth plates are still open; the eligible age range was later broadened. In a 52-week randomized phase 3 trial in children aged 5 to under 18, annualized growth velocity was 1.57 cm/year higher with vosoritide than placebo (Savarirayan et al., Lancet, 2020) (PMID 32891212). An open-label extension reported sustained growth effects for up to 6 years, with an estimated extra 5.75 cm of height after 3 years versus untreated children (PMID 39740666). Common side effects are mild injection site reactions and transient drops in blood pressure (PMID 40821249).

03 · Regulatory status

Vosoritide (Voxzogo) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Vosoritide (Voxzogo) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?

Vosoritide (Voxzogo) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.

Explore lawful options (free intake)

About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.

04 · Administration routes

  • Subcutaneous injection (daily)

References

  1. [1]Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial Lancet, 2020. PMID 32891212
  2. [2]Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study Med, 2025. PMID 39740666
  3. [3]Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence Cureus, 2025. PMID 40821249

Primary literature

Related peptides in Bone

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.